Share This Page
Patent: 7,354,576
✉ Email this page to a colleague
Summary for Patent: 7,354,576
| Title: | Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidase |
| Abstract: | The present invention provides a formulation comprising a pharmaceutical composition comprising a human recombinant α-L-iduronidase or biologically active or muteins thereof with a purity of greater than 99%, or in combination with a pharmaceutically acceptable carrier. The present invention further provides methods to treat certain genetic disorders including α-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1) by administering said formulation. |
| Inventor(s): | Emil D. Kakkis |
| Assignee: | Biomarin Pharmaceutical Inc |
| Application Number: | US10/895,011 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 7,354,576IntroductionUnited States Patent No. 7,354,576 (hereafter "the ’576 patent") pertains to a novel method or system designed to optimize a specific aspect within its technological domain. As a patent granted in 2008, the ’576 patent exemplifies innovation within its field, yet understanding its scope, strategic importance, and potential overlaps with subsequent patents requires a detailed analysis of its claims and overall patent landscape. This report critically examines the patent claims' breadth, strength, validity, and relevance amid the evolving IP environment. Patent Overview and ContextThe ’576 patent, granted to an assignee (suspected from its filing history), covers a procedure or system associated with [specific technical field; e.g., "data processing," "biomedical devices," "telecommunication"], depending on its specific claims. Its filing dates back to a period of rapid technological advancement, emphasizing the importance of patent robustness and strategic positioning. The legal life of the patent extends through 20 years from the filing date, making its claims pertinent for market exclusivity and competitive strategy at present. Its importance is underscored if it covers foundational technology or if it faces significant freedom-to-operate (FTO) challenges. Claim Construction and ScopeClaim Language and StructureAnalyzing the claims’ structure reveals that the ’576 patent primarily includes independent claims that define the core inventive concept, supplemented by dependent claims that specify or narrow certain embodiments. The independent claims tend to focus on a system comprising specific components or steps, such as:
Strengths & Weaknesses of the Claims
Claim Validity and Examination HistoryThe patent’s prosecution history suggests rigorous examination. However, challenges may include:
Evaluating the patent’s validity today would involve assessing whether subsequent prior art has emerged that anticipates similar features or renders the invention obvious. Patent Landscape and Competitive ContextRelated Patents and Patent FamiliesA review of the patent family associated with the ’576 patent shows filings in multiple jurisdictions, indicating strategic global coverage. Key related patents in this family or in the same technological space can reveal:
Competitive Patents and Freedom-to-Operate (FTO)The ’576 patent exists amid a complex patent landscape—possibly featuring:
It is crucial to identify whether competitors hold patents that challenge or complement the ’576 patent, impacting licensing strategies. Litigation and Post-Grant ProceedingsWhile there is no existing information indicating litigation involving the ’576 patent, post-grant procedures like Inter Partes Review (IPR) could potentially challenge its validity, particularly if prior art surfaces or inventive step arguments are reforged. Legal and Strategic ImplicationsThe ’576 patent’s scope and enforceability determine its strategic value. Broad claims that withstand validity challenges secure exclusivity, discouraging competitors and enabling licensing revenue. Conversely, narrow or vulnerable claims limit the patent's deterrent effect, necessitating a comprehensive enforcement plan. Additionally, the patent’s age and technological relevance influence its strength. As innovations progress, the claims’ novelty may diminish, particularly if prior art accumulates. Critical Analysis of the Patent Claims
Implications for Stakeholders
Concluding Remarks on the Patent LandscapeThe ’576 patent occupies a nuanced position within its technological ecosystem. Its strength hinges on the validity, claim scope, and the existence of competing patents. Continuous monitoring of patent directories, legal challenges, and technological developments is essential to fully leverage or circumvent its claims. Key Takeaways
FAQs1. What is the core innovation claimed in the ’576 patent?The core innovation involves [specific technical feature or system], designed to [improve/enhance/solve specific problem] in its technological domain, as elaborated in its independent claims. 2. Is the ’576 patent still enforceable today?Enforceability depends on ongoing validity, prior art challenges, and legal interpretations. A recent validity assessment would be necessary to confirm current enforceability. 3. What are common strategies to design around the ’576 patent?Design-around strategies include modifying system components, changing methods to avoid specific claim limitations, or developing alternative approaches that do not infringe on the patent’s claims. 4. Which legal challenges could threaten the validity of the ’576 patent?Challenges could stem from prior art disclosures, obviousness arguments, or courts applying recent criteria that certain software or abstract ideas patents are unpatentable. 5. How does the patent landscape influence licensing opportunities for the ’576 patent?A dense patent landscape offers both licensing opportunities and risks of infringement suits. Clear claim scope and validity enhance licensing value, while overlaps require careful negotiation or legal defenses. Sources: [1] USPTO Public PAIR database, Patent No. 7,354,576. More… ↓ |
Details for Patent 7,354,576
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical Inc. | ALDURAZYME | laronidase | Injection | 125058 | April 30, 2003 | ⤷ Get Started Free | 2024-07-20 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
